Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05105321
PHASE4

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

Sponsor: Tang Yida

View on ClinicalTrials.gov

Summary

The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).

Official title: Efficacy and Safety of Berberine on Primary Prevention of Cardiovascular Diseases and Diabetes in Metabolic Syndrome: a Randomized, Controlled Trial

Key Details

Gender

All

Age Range

40 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

5200

Start Date

2021-12

Completion Date

2028-12

Last Updated

2021-11-03

Healthy Volunteers

No

Interventions

DRUG

Berberine

The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily

BEHAVIORAL

Healthy lifestyle intervention

Healthy lifestyle intervention will be launched according to the "Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019", including health lectures, health information promotion, health manual and so on.

Locations (1)

Peking University Third Hospital

Beijing, Beijing Municipality, China